"News in Brief." Expert Review of Obstetrics & Gynecology, 8(6), pp. 497–498
Notes
Sources: Ledermann JA, Perren TJ, Raja FA et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. Presented at: European Cancer Congress 2013. Amsterdam, The Netherlands, 27 September–1 October 2013; European cancer congress news: http://eccamsterdam2013.ecco-org.eu/Global/News/ECC-2013-Press-Releases-EN/2013/09/Biological-therapy-with-cediranib-improves-survival-in-women-with-recurrent-ovarian-cancer.aspx